A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections.

J Transl Med · 2019 · PMC6708164 · PMID 31443716

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The incidences of streptococcal pharyngitis, AOM with otorrhea and wheezing were lower in children given OM-85 for 3 months, but the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.